[Sleep disorders associated with treatment with rimonabant].
Sempere
A P
AP
Giner-Bernabeu
J C
JC
Berenguer-Ruiz
L
L
Selles-Galiana
M F
MF
Hernandez-Rubio
L
L
Lezcano-Rodas
M
M
D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D000077285:Rimonabant; D012893:Sleep Wake Disorders / Q000139:chemically induced*
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant